SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
Tower 4, 727 Collins Street Docklands VIC 3008
Tel : +61 3 9615 9800 or 61 1300 554 474many shareholders in this company have unclaimed money due to them - deListed provides a tracing service for a small administration fee that identifies where people can find unclaimed monies arising from compulsory acquisitions and also from dividend distributions, super contributions, inoperative bank, building society or credit union accounts, bequests and other sources - please click here for access to our Lost shares, Lost money?? service | 31/03/2022 |
delisted at the request of the Company, under listing rule 17.11 | 05/02/2007 |
we understand Hospira was successful with an offer of $4.10 per Mayne Pharma share | 05/02/2007 |
securities suspended from quotation following lodgement of the court orders with ASIC in relation to the scheme of arrangement whereby all the Company's shares will be acquired by Hospira Inc | 22/01/2007 |
we understand that on or about this date the company undertook, proposed to undertake or was the subject of the following corporate action: - Mayne Pharma shareholders will receive $4.10 cash under scheme with Hospira Inc - this corporate event may appear elsewhere in this company record | 22/01/2007 |
Mayne Group Limited (Mayne) undertook a number of transactions to separate the ownership of the international pharmaceutical business (to Mayne Pharma and its subsidiaries) - Mayne (now Symbion Health Limited) retained the domestic healthcare businesses - as a result of the demerger, Mayne shareholders held shares in both Symbion Health and Mayne Pharma - the demerger was undertaken via a Scheme of Arrangement whereby Mayne undertook a capital reduction under which a total of approximately $1.56 billion of contributed capital was returned to Mayne shareholders (capital reduction amount) - this amounted to approximately $2.45 per ordinary issued Mayne share - the capital reduction amount was applied on behalf of Mayne shareholders for the subscription of approximately 636 million new shares in Mayne Pharma - Mayne shareholders subscribed for one new Mayne Pharma share for every one Mayne share they held before the demerger and Mayne Pharma used the funds received on the issue of the new shares to repay outstanding loans to Mayne | 18/11/2005 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 06/12/2005 | Nora Scheinkestel | 4,100 | $2.470 | $10,127.00 |
| 06/12/2005 | John Sime | 10,000 | $2.520 | $25,200.00 |
| 29/11/2005 | Nora Scheinkestel | 11,746 | $2.690 | $31,597.00 |
| 08/11/2005 | Stuart James | -93,876 | $5.400 | $506,930.00 |
| 14/10/2005 | Nora Scheinkestel | 7,590 | $5.250 | $39,848.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Peter Wilcox | Chairman | 04/10/2005 |
| Thierry Soursac | Managing Director, CEO | 18/11/2005 |
| Rowan Russell | Director | 04/10/2005 |
| Nora Scheinkestel | Director | 04/10/2005 |
| John Sime | Director | 04/10/2005 |
| Tamara Joseph | General Counsel, Company Secretary | |
| D.C. Kiriacoulacos | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
